AMENDMENTS TO THE CLAIMS

Please amend claims 1, 3, 5, 7 as shown below. A complete listing of the claims that are, or were, in the instant application are presented according to revised 37 C.F.R. § 1.121.

Listing of Claims:

What is claimed is:

1. (Currently amended) A compound ~~comprising~~ of Formula I



I

wherein:

R1

is a branched chain C3 to C8 alkyl, C3 to C8 cycloalkyl, C4 to C8 alkyl-substituted alkyl, bicycloalkyl, 1-adamantyl, polyhaloalkyl, trialkylsilyl, ~~unsubstituted phenyl~~, or substituted phenyl;

R2 and R3

are each independently of the other unsubstituted or substituted aromatic rings, chosen from phenyl, pyridyl, pyrimidinyl, furyl, thiophenyl, pyrazinyl, pyrrolyl, pyrazolyl, 1,2,4-triazolyl, naphthyl, fluorenonyl, xanthenyl, 4-oxo-1,4-dihydro-

(1,8)naphthyridinyl, thiazolyl, isothiazolyl, 1,3,4-thiadiazolyl, benzo-1,2,3-thiadiazolyl, oxazolyl, imidazolyl, quinolinyl, or isoquinolinyl, where a substituent on the rings is one or more chosen independently from hydrogen, C1 to C4 alkyl, alkoxy, alkoxyalkyl, hydroxy, amino, alkylamino, dialkylamino, acylamino, halo, haloalkyl, hydroxyalkyl, dihydroxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, unsubstituted or substituted alkylphenyl, unsubstituted or substituted phenyl, unsubstituted or substituted phenoxy, nitro, cyano, alkylthio, alkylsulfonyl, aminoalkyl, carboxyalkyl, or sulfonylalkyl;

and

R4

is hydrogen, alkylthio, alkylthioalkyl, alkyloxyalkyl, acyloxyalkyl, alkyl, acyl, trialkylsilyl, ~~or is taken together with R3 and the O in Formula I to form a lactone ring;~~

~~and~~ or the salts, stereoisomers, and tautomers thereof.

2. (Original) The compound of claim 1, wherein R1 is *tert*-butyl.

3. (Currently amended) The compound of claim 1, wherein at least one of R2 and R3 further is substituted with a substituent forming a cyclic structure on adjacent atoms of the aromatic ring.

4. (Original) The compound of claim 3, wherein the substituent is selected from the group consisting of 1,2-methylenedioxy and 1,2-difluoromethylenedioxy.

5. (Currently amended) The compound of claim 1, wherein R2 is selected from the group consisting of phenyl, 3,5-dimethylphenyl, 2,4-dimethylphenyl, 3-methylphenyl, 4-methylphenyl,and 2-methylphenyl, ~~and 3,4-methoxydioxyphenyl.~~

6. (Original) The compound of claim 1, wherein R3 is selected from the group consisting of phenyl, 3-pyridyl, 3-methoxy-2-methylphenyl, 3-ethoxy-2-methylphenyl, 3-methoxy-2-ethylphenyl, 4-ethylphenyl, 2,6-difluorophenyl, 2,3-dimethylphenyl, 3-chloro-2-methylphenyl, and 3-bromo-2-methylphenyl.

7. (Currently amended) The compound of claim 1, wherein halo is selected from the group consisting of fluoro, chloro, bromo, and iodo, ~~and combinations thereof.~~

8. (Original) The compound of claim I, wherein Formula I is in its tautomeric form as Formula II:



II

9. (Original) The tautomeric compound of claim 8, wherein R3 and R4 and O together form a cyclic structure resulting in a lactone.

10. (Original) The compound of claim 9, wherein the lactone is selected from the group consisting of:











and



11. (Original) The compound of claim I, wherein Formula I is in its isomeric form as Formula III:



III

12. (Original) The isomeric compound of claim 11, wherein R1 is *tert*-butyl, R2 is 3,5-dimethylphenyl, and R3 is 2-trifluoromethylphenyl or 2-methyl-3-methoxyphenyl.

13. (Original) The isomeric compound of claim 12, wherein the compound is selected from the group consisting of:



and



14. (Original) The compound of claim 1, wherein the compound is selected from the group consisting of:


































O
N
H
N


N
O
O
F
N
H
N
F
F
F
F


N
F
F
F
O
NH
O














O
N
H
N


N
HN
O
O
Cl


F
H
N
F
N
O
O
N








N
HN
O
O


O
O
O
NH
N


N
HN
O
























































































































N
HN
O
F
F
F


N
HN
O
N








N
O
NH
O


H
N
N
O
O


N
HN
O
Cl
Cl


N
HN
O
Cl
Cl


N
H
N
O
Br


O
NH
N


N
H
N
O
Cl


N
H
N
O


N
HN
O
















F
H
N
N
O
F


H
N
N
O


H
N
N
O
O


N
HN
O
F
F


H
N
N
O


H
N
N
O
O


F
F
O
NH
N


N
HN
O
F


N
HN
O
F


N
HN
O


H
N
N
O
O
O
O


N
HN
O
Br


N
HN
O
Cl


N
HN
O
F
F


O
O
O
N
H
N


N
HN
O
F
F
F


O
O
N
H
N


N
HN
O



















and



15. (Original) A method of controlling gene expression comprising contacting an

ecdysone receptor gene switch with a compound of Formula I



I

wherein:

R1

is a branched chain C3 to C8 alkyl, C3 to C8 cycloalkyl, C4 to C8 alkyl-substituted alkyl, bicycloalkyl, 1-adamantyl, polyhaloalkyl, trialkylsilyl, unsubstituted phenyl, or substituted phenyl;

R2 and R3

are each independently of the other unsubstituted or substituted aromatic rings, chosen from phenyl, pyridyl, pyrimidinyl, furyl, thiophenyl, pyrazinyl, pyrrolyl, pyrazolyl, 1,2,4-triazolyl, naphthyl, fluorenonyl, xanthenyl, 4-oxo-1,4-dihydro-(1,8)naphthyridinyl, thiazolyl, isothiazolyl, 1,3,4-thiadiazolyl, benzo-1,2,3-thiadiazolyl, oxazolyl, imidazolyl, quinolinyl, or isoquinolinyl, where a substituent on the rings is one or more chosen independently from hydrogen, C1 to C4 alkyl, alkoxy, alkoxyalkyl, hydroxy, amino, alkylamino, dialkylamino, acylamino, halo, haloalkyl, hydroxyalkyl, dihydroxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, unsubstituted or substituted alkylphenyl, unsubstituted or substituted phenyl, unsubstituted or substituted phenoxy, nitro, cyano, alkylthio, alkylsulfonyl, aminoalkyl, carboxyalkyl, or sulfonylalkyl;

and

R4

is hydrogen, alkylthio, alkylthioalkyl, alkyloxyalkyl, acyloxyalkyl, alkyl, acyl, trialkylsilyl, or is taken together with R3 and the O in Formula I to form a lactone ring;

and the salts, stereoisomers, and tautomers thereof.

16. (Original) The method of claim 15, wherein R1 is *tert*-butyl.

17. (Original) The method of claim 15, wherein at least one of R2 and R3 is substituted with a substituent forming a cyclic structure on adjacent atoms of the aromatic ring.

18. (Original) The method of claim 17, wherein the substituent is selected from the group consisting of 1,2-methylenedioxy and 1,2-difluoromethylenedioxy.

19. (Original) The method of claim 15, wherein R2 is selected from the group consisting of phenyl, 3,5-dimethylphenyl, 2,4-dimethylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methylphenyl, and 3,4-methoxydioxyphenyl.

20. (Original) The method of claim 15, wherein R3 is selected from the group consisting of phenyl, 3-pyridyl, 3-methoxy-2-methylphenyl, 3-ethoxy-2-methylphenyl, 3-methoxy-2-ethylphenyl, 4-ethylphenyl, 2,6-difluorophenyl, 2,3-dimethylphenyl, 3-chloro-2-methylphenyl, and 3-bromo-2-methylphenyl.

21. (Original) The method of claim 15, wherein halo is selected from the group consisting of fluoro, chloro, bromo, iodo, and combinations thereof.

22. (Original) The method of claim 15, wherein Formula I is in its tautomeric form as Formula II:



II

23. (Original) The method of claim 22, wherein in the tautomeric form, R3 and R4 and O together form a cyclic structure resulting in a lactone.

24. (Original) The method of claim 23, wherein the lactone is selected from the group consisting of:











and



25. (Original) The method of claim I5, wherein Formula I is in its isomeric form as Formula III:



III

26. (Original) The isomeric method of claim 25, wherein R1 is *tert*-butyl, R2 is 3,5-dimethylphenyl, and R3 is 2-trifluoromethylphenyl or 2-methyl-3-methoxyphenyl.

27. (Original) The isomeric method of claim 26, wherein the compound is selected from the group consisting of:



and



28. (Original) The method of claim 15, wherein the compound is selected from the group consisting of:




















Cl
O
O
N
H
N


N
O
F
O
N
H
N
F


N
HN
O
O














N
F
F
F
O
NH
O


O
O
N
N
H
S
F
F
F


N
O
O
F
N
H
F
N


N
O
NH
O


O
O
N
N
H
S


H
N
O
N
O






































N
HN
O
O
Cl


H
N
N
N
O
S
N


N
HN
O
Cl
O


































































































N
HN
O
F
F
F


N
HN
O
N


N
HN
O
Cl
N


H
N
N
N
O
Cl


H
N
N
O
O


N
O
NH
O


H
N
N
O
O


N
HN
O
Cl
Cl


N
HN
O
Cl
Cl


N
H
N
O
Br


O
NH
N


N
H
N
O
Cl


N
H
N
O


N
HN
O
















F
H
N
N
O
F


H
N
N
O


H
N
O
N
O


N
HN
O
F
F


H
N
N
O


H
N
N
O
O


F
F
O
NH
N


N
HN
O
F


N
HN
O
F


N
HN
O


N
H
N
O
O
O
O


N
HN
O
Br


N
HN
O
Cl


N
HN
O
F
F


O
O
O
N
H
N


N
HN
O
F
F
F


O
O
N
H
N


N
HN
O



















and